Regeneron s REGEN-COV First Antibody that Improves COVID-19 Survival in Hospitalized Patients freerepublic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freerepublic.com Daily Mail and Mail on Sunday newspapers.
REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ EUA supported by pivotal Phase 3 data showing 1,200 mg dose reduced risk of hospitalization or death by 70% Only antibody therapy currently.
Share this article
TARRYTOWN, N.Y., May 17, 2021 /PRNewswire/
Patients treated with REGEN-COV had 4-day shorter duration of symptoms and significantly reduced viral load compared to placebo
Similar efficacy observed with both doses (1,200 mg and 2,400 mg); U.S. FDA is currently reviewing request to add lower 1,200 mg dose to EUA
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of detailed results from the Phase 3 pivotal trial showing REGEN–COV™ (casirivimab with imdevimab) significantly reduced the risk of hospitalization or death, shortened symptom duration and reduced viral load in non-hospitalized patients (outpatients) with COVID-19. These data were presented at the 2021 American Thoracic Society International Conference (ATS 2021) in the
Phase 3 Data Presented at ATS 2021 Show REGEN-COV™ (casirivimab with imdevimab) Reduced Risk of Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.